News

MaaT Pharma sees submission

Country
France

MaaT Pharma SA of France expects to make its first regulatory submission to the European Medicines Agency in June following a successful Phase 3 trial of its microbiome therapy and a capital increase of €13 million from a private share placement. The capital increase was announced on 27 March, not long after the company reported the latest clinical data for its therapy. The therapy, MaaT013, is being developed for patients with acute graft-versus-host disease with gastrointestinal involvement. 

New breath test at Owlstone

Country
United Kingdom

Owlstone Medical Ltd is to receive an equity investment of up to $2.3 million from the US Cystic Fibrosis Foundation to develop a new breath test to detect a bacterial infection in patients with cystic fibrosis. The UK company has developed technology that can detect biological information from volatile organic compounds and respiratory droplets in breath. The newest project will involve developing a test for Pseudomonas aeruginosa, a Gram negative bacterial infection that can be particularly dangerous for people with compromised immune systems.

Funding for Augustine Therapeutics

Country
Belgium

Novo Holdings A/S and Jeito Capital have co-led a new financing for Augustine Therapeutics NV of Belgium to support clinical development of the company’s candidate treatment for Charcot-Marie-Tooth disease, an inherited disorder that can cause nerve damage. The oversubscribed Series A financing raised a total of €78 million which includes an earlier sum of €17.5 million generated in 2024. Altogether 11 investors supported the company, including the US-based Charcot-Marie-Tooth Research Foundation. The closing of the Series A round was announced on 24 March.

EU investment policy

Country
Belgium

The European Commission launched a new proposal on 19 March to stimulate private investment in industry and harmonise rules for trading in securities. The plan would essentially try to encourage citizens with large cash savings in banks in the EU to invest a portion of these assets in industry, including in small and medium size companies, to stimulate innovation and boost growth. The plan, called the savings and investment union, is a new version of an earlier capital markets union proposal that was introduced in 2014 but failed to gain traction.

Retirement of Francis Collins from the NIH

Country
United States

Francis Collins, a geneticist and director of the US National Institutes of Health for 12 years, retired from his position on 28 February, with a tribute to his colleagues and the institution that they support. “The National Institutes of Health is the world’s foremost medical research institution. It has been rightfully called the ‘crown jewel’ of the federal government for decades. It has been the greatest honour of my life to be part of this institution in various roles over the last four decades,” he said in a statement.

Callio debuts with ADC plan

Country
United States

A new biotech company has been launched in Seattle, US, and Singapore, with the goal of advancing the technology for antibody-drug conjugates - treatments for cancer that use an antibody and linker to deliver a cytotoxic agent to cancer cells. The company, Callio Therapeutics Inc, is developing ADCs that would be equipped with more than one cytotoxic payload. The company says this structure could increase the efficacy of ADCs, a drug class which is attracting developers across the industry.

Valneva sees higher vaccine sales

Country
France

Valneva SE, developer of the world’s first vaccine against chikungunya virus, is forecasting higher sales this year and more investment in R&D as it advances new products in the clinic against infectious diseases. Product sales this year are expected to reach €170 to €180 million, up from €163.3 million in 2024. This will drive positive cash flow for the business enabling an increase in R&D spending to between €90 to €100 million, up from €74.1 million in 2024.

InflaRx extends cash runway

Country
Germany

InflaRx NV has extended its cash runway into 2027 following a public share offering in February that raised €28.7 million. The forecast was issued on 20 March in the German company’s 2024 annual report which showed an operating loss of €53 million on the back of significant outlays for research and development. R&D expenditure was €35.4 million, more than twice the sums spent to cover the company’s other business expenses. Founded in 2007, InflaRx is building a portfolio of drugs for inflammatory diseases that target the complement system, a key component of the innate immune system.

New obesity partnership

Country
Denmark

Zealand Pharma A/S is partnering with the Roche Group to co-develop a candidate drug for obesity discovered by the Danish company with potential as both a monotherapy and in combination with other drugs. This includes in combination with an obesity asset owned by Roche. The drug is petrelintide, a long-acting amylin analogue which has delivered reductions in body weight of up to a mean 8.6% in early clinical studies. Amylin is a peptide hormone that restores sensitivity to leptin, a satiety hormone that enables people to feel naturally full after having eaten a meal.

New finding on antimicrobial resistance

Country
Israel

A study from the Weizmann Institute of Science in Israel has revealed an unexpected immune function of proteasomes, the cellular machinery primarily known for protein degradation. The research, published in Nature on 5 March, demonstrates that proteasomes play a direct role in innate immunity by generating antimicrobial peptides (AMPs) that combat bacterial infections. This discovery not only deepens our understanding of cellular defence mechanisms but also opens new avenues for addressing antibiotic resistance.